### Edgar Filing: SYNBIOTICS CORP - Form 8-K

SYNBIOTICS CORP Form 8-K April 30, 2002

\_\_\_\_\_\_

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-----

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2002

SYNBIOTICS CORPORATION (Exact name of registrant as specified in its charter)

Commission file number 0-11303

California
(State or other jurisdiction of incorporation)

95-3737816 (I.R.S. Employer Identification No.)

11011 Via Frontera San Diego, California (Address of principal executive offices)

92127 (Zip Code)

Registrant's telephone number, including area code: (858) 451-3771

\_\_\_\_\_

Item 4. Changes in Registrant's Certifying Accountant

On April 24, 2002, we dismissed PricewaterhouseCoopers LLP as our independent auditor, and appointed Levitz, Zacks & Ciceric as our independent auditor. Our Audit Committee recommended the change of auditor, and the change was approved by our Board of Directors.

The reports of PricewaterhouseCoopers LLP on our financial statements for the years ended December 31, 2001 and 2000 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles except that the report of PricewaterhouseCoopers LLP on the December 31, 2000 financial statements contained an explanatory paragraph expressing substantial doubt relating to the Company's ability to continue as a going concern. During our two most recent years and subsequent interim period through April 24, 2002, there were no disagreements with PricewaterhouseCoopers LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of

## Edgar Filing: SYNBIOTICS CORP - Form 8-K

PricewaterhouseCoopers LLP, would have caused them to make reference to the subject matter of such disagreements in connection with their reports, nor were there any reportable events as defined in Regulation S-K Item 304(a)(1)(v).

We have requested PricewaterhouseCoopers LLP to furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of that letter is filed as Exhibit 16 to this Form 8-K.

- Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
  - a) Financial statements of businesses acquired

Not applicable.

b) Pro forma financial information

Not applicable.

- c) Exhibits
  - 16 Letter from PricewaterhouseCoopers LLP regarding change in certifying accountant.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYNBIOTICS CORPORATION

Date: April 30, 2002 /s/ Michael K. Green

\_\_\_\_\_

Michael K. Green Senior Vice President - Finance and Chief Financial Officer

-1-

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.

EXHIBITS

TO

FORM 8-K

UNDER

SECURITIES EXCHANGE ACT OF 1934

SYNBIOTICS CORPORATION

# Edgar Filing: SYNBIOTICS CORP - Form 8-K

## EXHIBIT INDEX

Exhibit No.	Exhibit
16	Letter from PricewaterhouseCoopers LLP regarding change in certifying accountant.